Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Rallybio Stock (NASDAQ: RLYB) stock price, news, charts, stock research, profile.
Day Range- - - | 52 Wk Range4.540 - 15.890 | Open / Close- / - | Float / Outstanding31.236M / 37.838M |
Vol / Avg.0 / 118.801K | Mkt Cap256.544M | P/E- | 50d Avg. Price6.120 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float31.236M | EPS-2.050 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-14 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.540 | -0.600 | -0.0600 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Rallybio (NASDAQ: RLYB) through any online brokerage.
Other companies in Rallybio’s space includes: Molecular Partners (NASDAQ:MOLN), Innate Pharma (NASDAQ:IPHA), KalVista Pharma (NASDAQ:KALV), Larimar Therapeutics (NASDAQ:LRMR) and LianBio (NASDAQ:LIAN).
The latest price target for Rallybio (NASDAQ: RLYB) was reported by JP Morgan on Friday, December 9, 2022. The analyst firm set a price target for 21.00 expecting RLYB to rise to within 12 months (a possible 209.73% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Rallybio (NASDAQ: RLYB) is $6.78 last updated February 2, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Rallybio.
Rallybio’s Q4 earnings are confirmed for Tuesday, March 14, 2023.
There is no upcoming split for Rallybio.
Rallybio is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.